How We Elevate Mental Wealth
MINDCURE isn’t your typical pharma company.
We’re revolutionizing mental health treatment options by combining these intimately related spheres:
Meet our cutting-edge digital therapeutics platform optimizing healing for mental health clinicians and patients
Discover how we identify opportunities and develop treatment pathways
Making Mental Wealth Accessible
iSTRYM is a first-of-its-kind software application that optimizes the healing journey for both patients and clinicians — before, during, and after therapy sessions. By bringing together a variety of healing solutions, such as convenient user dashboards, guided mindfulness practices, intelligent data analysis, and more, iSTRYM optimizes therapy.
Access a robust repository of treatment protocols and care packages
Individualize care with digitized, data-driven analytics
Monitor client status before, during, and after sessions for deeper insights that don’t interrupt care
Own your mental wellness journey with automated support, personalized to your custom care needs and preferences
Explore guided practices to elevate your mindset
MINDCURE’s research team is constantly uncovering opportunities to promote healing. We develop psychedelic treatment protocols and synthesize compounds for commercial use in clinical studies that show therapeutic potential.
The Desire Project
Using MDMA-Assisted Psychotherapy to Help Women Overcome Lack of Desire
Hypoactive Sexual Desire Disorder (HSDD) is a common female sexual disorder characterized by persistent low sexual desire and emotional distress that are not attributable to an existing medical condition or relationship issue.
In the U.S. alone, HSDD affects an estimated 9.5 million premenopausal women.
Learn more about the research MINDCURE is doing to address this under researched and under treated condition.
The Ibogaine Project
Sustainable supply of synthesized ibogaine
MINDCURE is manufacturing synthetic ibogaine in order to provide researchers and clinicians with the resources they need to promote healing.
Indications include addiction, migraines, cluster headaches, neuropathic pain, treatment-resistant mood disorders, and more.
There is a growing need for a sustainable and reliable supply of ibogaine.
Our technology confirms our starting point by discovering target receptors, methods, and opportunities for healing.
Product Discovery & Lead Optimization
We analyze the molecular structures of psychedelic compounds, such as ibogaine, and synthesize novel substances.
We conduct clinical trials with novel, synthetic, and classic psychedelics to discover new indications and shape a baseline for treatment protocols.
From pain point to product, our team continues to substantiate decades of scientific evidence around psychedelics for their potential in mental health treatments.
MINDCURE is manufacturing synthetic ibogaine in order to provide researchers and clinicians with the resources they need to promoting healing related to:
Treatment-resistant mood disorders
Wellness products like you’ve never seen. We’re promoting mental health and mental wealth with nootropics, adaptogens, and more.
We’re never idle — between researching, identifying, and perfecting new formulations with therapeutic benefits.
Invest in the Moment
Why invest in psychedelic therapy?
See who's executing our ground-breaking approaches to psychedelic treatment and technology. We’re industry experts in biotech, life sciences, data research, new product discovery, integrative technology, biomedical innovation, and health care. Our team is at the forefront of scientific discovery.
Co-Founder & CEO
Dr. Dan Engle, MD
Chief Technology Officer
Chief Operating Officer
Chairman of the Board of Directors
Mark Kelly, MSc
Research & Development Manager
Dr. Wolfram Tetzlaff, MD, PhD
Hector MacKay-Dunn, Q.C.
Dr. Jason Wallach, PhD